EP3065772
COMBINATIONS OF CHECKPOINT INHIBITORS AND THERAPEUTICS TO TREAT CANCER
Status:
EP einkaleyfi: Þýðing ekki lögð innEP appl. date:
5.11.2014EP published:
24.7.2024EP application number:
14859634.9
EPO information:
European Patent Register
Max expiry date:
4.11.2034
Title in English:
COMBINATIONS OF CHECKPOINT INHIBITORS AND THERAPEUTICS TO TREAT CANCERLanguage of the patent:
English
Timeline
Today
5.11.2014EP application
24.7.2024EP Publication
Owner
Name:
Cognate Bioservices, Inc.Address:
7513 Connelley Drive, Hanover, MD 21076, US
Name:
NorthWest Biotherapeutics, Inc.Address:
4800 Montgomery Lane, Suite 800, Bethesda, MD 20814, US
Name:
The Regents of the University of CaliforniaAddress:
1111 Franklin Street, 12th Floor, Oakland, CA 94607, US
Name:
REVIMMUNE, INC.Address:
7513 Connelley Drive, Hanover MD 21076, US
Inventor
Name:
BOSCH, Marnix, LeoAddress:
Clyde Hill, WA 98004, US
Name:
GANJEI, James, KellyAddress:
Bethesda, MD 20814, US
Name:
POWERS, Linda, F.Address:
Bethesda, MD 20814, US
Name:
LIAU, Linda, M.Address:
Los Angeles, CA 90077, US
Name:
PRINS, Robert, M.Address:
Pacific Palisades, CA 90272, US
Priority
Number:
201361900355 PDate:
5.11.2013Country:
US
Number:
201361900309 PDate:
5.11.2013Country:
US
Classification
Categories:
A61K 39/00, A61K 39/39, A61K 39/395, A61K 38/20, C07K 16/28, A61N 5/10, A61P 35/04, A61P 43/00, A61K 35/15, A61P 35/00, A61P 35/02, A61P 37/04